Literature DB >> 30463885

Using a 10-step framework to support the implementation of an evidence-based clinical pathways programme.

Emilia J Flores1,2, Nikhil K Mull3,4, Julia G Lavenberg3, Matthew D Mitchell3, Brian F Leas3, Austin Williams3, Patrick J Brennan3,4, Craig A Umscheid3,4.   

Abstract

BACKGROUND: Integration of evidence into practice is suboptimal. Clinical pathways, defined as multidisciplinary care plans, are a method for translating evidence into local settings and have been shown to improve the value of patient care.
OBJECTIVE: To describe the development of a clinical pathways programme across a large academic healthcare system.
METHODS: We use a 10-step framework (grounded in the Knowledge-to-Action framework and ADAPTE Collaboration methodology for guideline adaptation) to support pathway development and dissemination, including facilitating clinical owner and stakeholder engagement, developing pathway prototypes based on rapid reviews of the existing literature, developing tools for dissemination and impact assessment. We use a cloud-based technology platform (Dorsata, Washington, DC) to assist with development and dissemination across our geographically distributed care settings and providers. Content is viewable through desktop and mobile applications. We measured programme adoption and penetration by examining number of pathways developed as well as mobile application use and pathway views.
RESULTS: From 1 February 2016 to 30 April 2018, a total of 202 pathways were disseminated. The three most common clinical domains represented were oncology (46.5%, n=94), pulmonary/critical care (8.9%, n=18) and cardiovascular medicine (7.4%, n=15). Users opting to register for a personal account totalled 1279; the three largest groups were physicians (45.1%, n=504), advanced practice providers (19.5%, n=245) and nurses (19.1%, n=240). Pathway views reached an average of 2150 monthly views during the last 3 months of the period. The majority of pathways reference at least one evidence-based source (93.6%, n=180).
CONCLUSIONS: A healthcare system can successfully use a framework and technology platform to support the development and dissemination of pathways across a multisite institution. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical decision support; clinical pathway; dissemination and implementation; evidence based medicine; evidence-based framework; quality improvement

Mesh:

Year:  2018        PMID: 30463885     DOI: 10.1136/bmjqs-2018-008454

Source DB:  PubMed          Journal:  BMJ Qual Saf        ISSN: 2044-5415            Impact factor:   7.035


  11 in total

1.  Next Steps in Improving Healthcare Value: AHRQ Evidence-based Practice Center Program-Applying the Knowledge to Practice to Data Cycle to Strengthen the Value of Patient Care.

Authors:  Amanda E Borsky; Emilia J Flores; Elise Berliner; Christine Chang; Craig A Umscheid; Stephanie M Chang
Journal:  J Hosp Med       Date:  2019-05       Impact factor: 2.960

2.  Health Technology Assessment Centers-an Infrastructure for Health Systems to Translate Evidence into Practice.

Authors:  Ravi N Sharaf; Dhruv Khullar; Craig A Umscheid
Journal:  J Gen Intern Med       Date:  2020-01-03       Impact factor: 5.128

3.  Australian guideline on prevention of foot ulceration: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease.

Authors:  Michelle R Kaminski; Jonathan Golledge; Joel W J Lasschuit; Karl-Heinz Schott; James Charles; Jane Cheney; Anita Raspovic
Journal:  J Foot Ankle Res       Date:  2022-07-06       Impact factor: 3.050

4.  Australian guideline on management of diabetes-related foot infection: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease.

Authors:  Robert J Commons; James Charles; Jane Cheney; Sarah A Lynar; Matthew Malone; Edward Raby
Journal:  J Foot Ankle Res       Date:  2022-06-09       Impact factor: 3.050

Review 5.  Australian guideline on diagnosis and management of peripheral artery disease: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease.

Authors:  Vivienne Chuter; Frank Quigley; Patrik Tosenovsky; Jens Carsten Ritter; James Charles; Jane Cheney; Robert Fitridge
Journal:  J Foot Ankle Res       Date:  2022-07-05       Impact factor: 3.050

6.  Development of a model care pathway for the management of Hymenoptera venom allergy: evidence-based key interventions and indicators.

Authors:  Maria Beatrice Bilò; Alice Corsi; Valerio Pravettoni; Donatella Bignardi; Patrizia Bonadonna; Oliviero Quercia; Marina Mauro; Elio Novembre; Rebecca Micheletti; Roberto Papa
Journal:  Clin Transl Allergy       Date:  2020-03-04       Impact factor: 5.871

7.  Interventions to Reduce Hospital Length of Stay in High-risk Populations: A Systematic Review.

Authors:  Shazia Mehmood Siddique; Kelley Tipton; Brian Leas; S Ryan Greysen; Nikhil K Mull; Meghan Lane-Fall; Kristina McShea; Amy Y Tsou
Journal:  JAMA Netw Open       Date:  2021-09-01

8.  Use of Clinical Pathways Integrated into the Electronic Health Record to Address the COVID-19 Pandemic.

Authors:  Allison H Bartlett; Sonya Makhni; Samantha Ruokis; Mary Kate Selling; Lauren Hall; Craig A Umscheid; Cheng-Kai Kao
Journal:  Infect Control Hosp Epidemiol       Date:  2022-03-22       Impact factor: 6.520

9.  Guidelines development protocol and findings: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease.

Authors:  Peter A Lazzarini; Anita Raspovic; Jenny Prentice; Robert J Commons; Robert A Fitridge; James Charles; Jane Cheney; Nytasha Purcell; Stephen M Twigg
Journal:  J Foot Ankle Res       Date:  2022-04-19       Impact factor: 3.050

10.  Australian guideline on offloading treatment for foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease.

Authors:  Malindu E Fernando; Mark Horsley; Sara Jones; Brian Martin; Vanessa L Nube; James Charles; Jane Cheney; Peter A Lazzarini
Journal:  J Foot Ankle Res       Date:  2022-05-05       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.